Literature DB >> 15634912

Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells.

Lori Broderick1, Sandra J Yokota, Joshua Reineke, Edith Mathiowitz, Carleton C Stewart, Maurice Barcos, Raymond J Kelleher, Richard B Bankert.   

Abstract

The implantation of small pieces of human primary lung tumor biopsy tissue into SCID mice results in a viable s.c. xenograft in which the tissue architecture, including tumor-associated leukocytes, tumor cells, and stromal cells, is preserved in a functional state. By monitoring changes in tumor volume, gene expression patterns, cell depletion analysis, and the use of function-blocking Abs, we previously established in this xenograft model that exogenous IL-12 mobilizes human tumor-associated leukocytes to kill tumor cells in situ by indirect mechanisms that are dependent upon IFN-gamma. In this study immunohistochemistry and FACS characterize the early cellular events in the tumor microenvironment induced by IL-12. By 5 days post-IL-12 treatment, the constitutively present human CD45(+) leukocytes have expanded and infiltrated into tumor-rich areas of the xenograft. Two weeks post-treatment, there is expansion of the human leukocytes and complete effacement of the tumor compared with tumor progression and gradual loss of most human leukocytes in control-treated xenografts. Immunohistochemical analyses reveal that the responding human leukocytes are primarily activated or memory T cells, with smaller populations of B cells, macrophages, plasma cells, and plasmacytoid dendritic cells capable of producing IFN-alpha. The predominant cell population was also characterized by FACS and was shown to have a phenotype consistent with a CD4(+) effector memory T cell. We conclude that quiescent CD4(+) effector memory T cells are present within the tumor microenvironment of human lung tumors and can be reactivated by the local and sustained release of IL-12 to proliferate and secrete IFN-gamma, leading to tumor cell eradication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634912     DOI: 10.4049/jimmunol.174.2.898

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Authors:  Kamel Ait-Tahar; Amanda P Liggins; Graham P Collins; Andrew Campbell; Martin Barnardo; Maite Cabes; Charles H Lawrie; Donald Moir; Chris Hatton; Alison H Banham; Karen Pulford
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

2.  Memory T cells in the chronic inflammatory microenvironment of nasal polyposis are hyporesponsive to signaling through the T cell receptor.

Authors:  Heather K Lehman; Michelle R Simpson-Abelson; Thomas F Conway; Raymond J Kelleher; Joel M Bernstein; Richard B Bankert
Journal:  J Assoc Res Otolaryngol       Date:  2012-02-04

3.  The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis.

Authors:  Catherine E Steding; Sung-tse Wu; Yanping Zhang; Meei-Huey Jeng; Bennett D Elzey; Chinghai Kao
Journal:  Immunology       Date:  2011-04-01       Impact factor: 7.397

4.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

5.  Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model.

Authors:  Sandra J Yokota; John G Facciponte; Raymond J Kelleher; Leonard D Shultz; Jenni L Loyall; Robert R Parsons; Kunle Odunsi; John G Frelinger; Edith M Lord; Scott A Gerber; Sathy V Balu-Iyer; Richard B Bankert
Journal:  Cancer Immun       Date:  2013-05-31

6.  Exosomes Represent an Immune Suppressive T Cell Checkpoint in Human Chronic Inflammatory Microenvironments.

Authors:  Gautam N Shenoy; Maulasri Bhatta; Jenni L Loyall; Raymond J Kelleher; Joel M Bernstein; Richard B Bankert
Journal:  Immunol Invest       Date:  2020-04-17       Impact factor: 3.657

7.  Clinical value of Pro-GRP and T lymphocyte subpopulation for the assessment of immune functions of lung cancer patients after DC-CIK biological therapy.

Authors:  Lijie He; Jing Wang; Dandan Chang; Dandan Lv; Haina Li; Heping Zhang
Journal:  Exp Ther Med       Date:  2017-11-16       Impact factor: 2.447

8.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments.

Authors:  Michelle R Simpson-Abelson; Vivek S Purohit; Wing Man Pang; Vandana Iyer; Kunle Odunsi; Todd L Demmy; Sandra J Yokota; Jenni L Loyall; Raymond J Kelleher; Sathy Balu-Iyer; Richard B Bankert
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

9.  Chitosan solution enhances the immunoadjuvant properties of GM-CSF.

Authors:  David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Journal:  Vaccine       Date:  2007-11-05       Impact factor: 3.641

10.  Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits.

Authors:  Marianne M Stanford; John W Barrett; Philippe-Alexandre Gilbert; Richard Bankert; Grant McFadden
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.